CCKAR Antibody

Code CSB-PA138502
Size US$166
Order now
Image
  • The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA138502(CCKAR Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: ×200)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
CCKAR
Alternative Names
CCKAR; CCKRA; Cholecystokinin receptor type A; CCK-A receptor; CCK-AR; Cholecystokinin-1 receptor; CCK1-R
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Synthetic peptide of Human CCKAR
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
Antigen affinity purification
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Form
Liquid
Tested Applications
ELISA,IHC
Recommended Dilution
Application Recommended Dilution
ELISA 1:1000-1:2000
IHC 1:10-1:50
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor for cholecystokinin. Mediates pancreatic growth and enzyme secretion, smooth muscle contraction of the gall bladder and stomach. Has a 1000-fold higher affinity for CCK rather than for gastrin. It modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene References into Functions
  1. CCK1R may play a role differing from CCK2R in colon carcinogenesis, nuclear CCK1R represents a potential biomarker for poor prognosis. PMID: 26508021
  2. Study shows downregulation of CCKAR gene expression in A1/A1 genotype of gallstone disease patients as compared with control with significant variation in its expression pattern in relation to polymorphism. PMID: 27287528
  3. Our study showed significantly higher expression of CCKAR and down regulation of CCKBR in pancreatic cancer as compared to control while CCKBR/GR was detected in majority of stomach cancer samples. Thus, our study suggests that CCK and Gs receptors may have diagnostic and therapeutic implications. PMID: 27072272
  4. The neurotransmitter cholecystokinin (CCK), along with its receptors, CCKAR and CCKBR, have been previously associated with psychiatric disorders, suggesting that variants near these genes may play a role in the pre-pulse/startle response in this cohort PMID: 26608796
  5. CCK-AR polymorphism is protective against functional dyspepsia. PMID: 26551933
  6. There is functional synergy between cholecystokinin receptors CCKAR and CCKBR in mammalian brain development. PMID: 25875176
  7. Age related differential expression of CCKAR in GBC may suggest two possible variants of the disease in this endemic belt. PMID: 25025063
  8. Y140A mutation within a cholesterol-binding motif results in ligand binding and activity characteristics similar to wild type CCK1R. in a high cholesterol environment PMID: 24825903
  9. The findings suggest that variants in the CCKAR gene may influence the risk of gallbladder cancer in women. PMID: 23701593
  10. A significant association of the cholecystokinin-A receptor (CCKAR) gene variation rs1800857 and language lateralization, is reported. PMID: 23341962
  11. The results showed that three individual haplotypes of CCKAR were strongly associated with increased risk of schizophrenia. PMID: 22825913
  12. Data suggest that CCK-1R expression is up-regulated in kidney tubules (but not in glomeruli) in patients with diabetic nephropathy; increased expression of CCK-1R in tubules appears to be biomarker of severity of proteinuria in these patients. PMID: 22396142
  13. data may suggest that the TM3 CRAC cholesterol-binding motif could be responsible for the cholesterol sensitivity of the CCK1R. PMID: 22021636
  14. CCKAR expression was significantly increased in gallbladder cancer compared to gallstone disease. PMID: 21813391
  15. Data indicate that the Homo-Phe derivative 2 (VL-0797) enhanced 12-fold the affinity for the rat CCK(1)-R affinity and 15-fold for the human CCK(1)-R relative to the reference compound 12 (VL-0395). PMID: 21728335
  16. An association is not found between cholecystokinin A receptor polymorphisms and antipsychotic induced weight gain in schizophrenia patients. PMID: 20732371
  17. LPS can up-regulate the expression of CCK-AR and CCK-BR mRNA in vascular endothelial cells. PMID: 19751565
  18. a 2-marker haplotype (rs1800855/rs1800857) in the CCKAR gene protected women against PD (P=0.004). In addition, we found two novel rare missense variations in the CCKBR gene (Lys329Asn and Pro446Leu) in two and one patient, respectively PMID: 20023595
  19. an intron 1 polymorphism in the cholecystokinin A receptor gene is associated with schizophrenia in males PMID: 19753663
  20. Significant association between polymorphism at the -85 locus of the CCKAR gene in patients with hallucination, especially patients with hallucination in delirium tremens. PMID: 12198366
  21. the presence of CCK receptors in human ductal pancreatic tumor samples is mainly due to CCK2 expression in residual pancreatic islets and CCK1 in pancreatic nerves. PMID: 12851875
  22. heterodimerization of type A and B cholecystokinin receptors forms a powerful signaling unit with potential clinical significance in promoting cell growth PMID: 14534299
  23. In this review, both localization and functional studies suggest that the motor effects of cholecystokinin are mediated by CCK1/CCKA receptors in humans. PMID: 15100163
  24. CCK-AR gene polymorphism may be involved in the neurobiology of panic disorder. PMID: 15108185
  25. CCK-AR gene is suggested to predispose persons to schizophrenia. PMID: 15363473
  26. analysis of partial and full agonism mediated by the human cholecystokinin-1 receptor PMID: 15632187
  27. Finds significant differences in intelligence for Cholecystokinin A receptor gene promoter polymorphisms A-81G and G-128T in community-living Japanese. PMID: 15723764
  28. the deficiency of CCK-R may be a key point leading to the impairment of gallbladder motor function and the pathogenesis of cholesterol gallstone formation PMID: 15786550
  29. possible role of the CCK-AR gene in the vulnerability to schizophrenia in patients with auditory hallucinations PMID: 17413443
  30. No evidence for the association between the CCK-AR gene and schizophrenia in the Japanese population. PMID: 17413452
  31. CCK-A receptor agonist, GI181771X, did not reduce body in obese patients, suggesting that CCK-A by itself does not have a central role in long-term energy balance. PMID: 17597711
  32. Responses of human esophageal sphincter sling and clasp fibers to cholecystokinin (CCK) and gastrin through CCK-A and -B receptors are reported. PMID: 18444993
  33. Report effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. PMID: 18776046

Show More

Hide All

Subcellular Location
Cell membrane; Multi-pass membrane protein.
Protein Families
G-protein coupled receptor 1 family
Database Links

HGNC: 1570

OMIM: 118444

KEGG: hsa:886

STRING: 9606.ENSP00000295589

UniGene: Hs.129

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*